ArticleOncology letters2025

Efficacy and safety of antiangiogenic therapy (bevacizumab or apatinib) plus chemotherapy in patients with platinum‑resistant recurrent ovarian cancer: A retrospective study.

Huifen Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.